GlucoLight Makes Non-Invasive Glucose Monitoring Real
This article was originally published in Start Up
When GlucoLight was founded in 2003 to bring to market an optical platform for non-invasive glucose monitoring-specifically, optical coherence tomography-its founders decided to set themselves apart from the pack in two ways. First, they would focus on generating clinical data, and letting that data speak for itself. The company has conducted six clinical trials to date. Second, they would validate its platform in an emerging market that needs a technological solution but that is well-validated from the clinical perspective: glucose monitoring in the hospital critical care environment. This market also offers a faster time to market because there is no requirement to miniaturize the monitor for the ICU environment. Part of a group of articles that includes: "Where are They Now? Checking in on Three Glucose Monitoring Companies," "A Decade of Development of SMSI: Will it Yield Improved Accuracy in CGM?" and "Pelikan Swoops in on the Big Four."
You may also be interested in...
Over a decade ago, the New England Journal of Medicine published a study identifying tight glycemic control in the intensive care unit as a critical step to improving patient outcomes. Today, a small pack of companies is trying to finally deliver on the promise.
Over a decade ago, the New England Journal of Medicine published a study identifying tight glycemic control in the intensive care unit as a critical step to improving outcomes. Today, GlySure and others are working on continuous glucose monitoring for the critical care environment to help deliver on that promise.
It's the end of a dynasty in the traditional market for self blood glucose testing--the test strips and hand-held monitors that patients have been using as the mainstay of their diabetes management. The four major companies, once differentiated players in a high growth market, have cut R&D and marketing budgets in the face of increasing commoditization. But a new era in continuous glucose monitoring has begun, and that sector is poised to grow in coming years, according to "US Markets for Diabetes Management Products," a report published in May 2009 by the Medtech Insight division of Elsevier Business Intelligence.